In a mouse model of systemic inflammation induced by lipopolysaccharide injection, psilocybin combined with eugenol reduced brain levels of several inflammatory cytokines. Pre-treatment with psilocybin alone or in a 1:50 combination with eugenol most effectively lowered COX-2 and TNF-α mRNA expression. Post-treatment with the 1:50 combination produced the strongest reductions across multiple markers, including IL-6 and IL-8, as measured by ELISA. Western blot confirmed decreased COX-2 and IL-1β proteins. The findings suggest that psilocybin and eugenol together have anti-inflammatory effects in the brain, potentially relevant to disorders like depression and PTSD.
Psilocybin and eugenol, both individually and combined, reduced inflammation in a mouse model of liver injury induced by lipopolysaccharides. Post-treatment administration produced stronger anti-inflammatory effects than pre-treatment. Psilocybin alone showed the most pronounced reduction of pro-inflammatory cytokines IL-1β, IL-6, and MCP-1, while the combination with eugenol (1:50 ratio) also strongly reduced COX-2 and TNF-α. Histological analysis indicated improved nuclear circularity and less inflammatory infiltration. Eugenol alone increased MCP-1 and GM-CSF, an adverse effect that was mitigated by co-administration with psilocybin. The findings suggest psilocybin and its combination with eugenol as potential therapies for hepatic inflammation.